Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chemo-enzymatic synthesis of C-9 acetylated sialosides

Jana Rauvolfova, Andre Venot and Geert-Jan Boons*

Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road, Athens, GA 30602, USA

Received 28 March 2008; received in revised form 1 May 2008; accepted 4 May 2008

Available online 8 May 2008

Abstract—A chemo-enzymatic synthesis of \[(5\text{-}acetamido\text{-}9\text{-}O\text{-}acetyl\text{-}3,5\text{-}dideoxy\text{-}\alpha\text{-}D\text{-}galacto\text{-}2\text{-}nonulopyranosylacid})\text{-}(2\rightarrow3)\text{-}O\text{-}(\beta\text{-D\text{-}galactopyranosyl})\text{-}(1\rightarrow3)\text{-}O\text{-}(2\text{-}acetamido\text{-}2\text{-}deoxy\text{-}\alpha\text{-}D\text{-}galactopyranosyl})\text{-}L\text{-}serine acetate (1) has been accomplished by a regioselective chemical acetylation of Neu5Ac (2) to give 9-O-acetylated sialic acid 3, which was enzymatically converted into CMP-Neu5,9Ac_2 (4) employing a recombinant CMP-sialic acid synthetase from Neisseria meningitis [EC 2.7.7.43]. The resulting compound was then employed for the enzymatic glycosylation of the C-3 hydroxyl of chemically prepared glycosylated amino acid 10 using recombinant rat \(\alpha\text{-}(2\rightarrow3)-O\text{-}sialyltransferase expressed in Spodooptera frugiperda [EC 2.4.99.4] to give, after deprotection of the N\text{a\text{-}benzoyloxycarbonyl (CBz)-protecting group of serine, target compound 1. The N\text{a\text{-}CBz-protected intermediate 11 can be employed for the synthesis of glycolipopeptides for immunization purposes.}

\[\text{© 2008 Elsevier Ltd. All rights reserved.}

Keywords: Chemo-enzymatic synthesis; Sialic acid; Acetylation; CMP-Neu5,9Ac_2; Immunogens

1. Introduction

Sialic acids are a family of approximately 50 naturally occurring 2-keto-3-deoxy-nononic acids that are involved in a wide range of biological processes.1–3 The C-5-amino derivative represents the long-known neuraminic acid and its amino function can either be acetylated (Neu5Ac) or glycolylated (Neu5Gc). As terminal components of glycoproteins and glycolipids, neuraminic acids are \(\alpha\text{-}(2\rightarrow3)\)- or \(\alpha\text{-}(2\rightarrow6)\)-linked to galactosides or \(\alpha\text{-}(2\rightarrow6)\)-linked to 2-acetamido-galactosides.4–6

Enzymatic acetylation, lactylation, sulfation, methylation and phosphorylation of free hydroxyls give a large structural diversity of sialic acids.3,7 O-Acetylation of sialic acids takes place in the Golgi apparatus by membrane bound \(O\text{-}acetyltransferases. Interestingly, different cell types show different substrate selectivity for acetylation of sialic acid indicating that there are different classes of acetyltransferases.2,3,8 Alternatively, it may be possible that adaptor proteins control the substrate specificity. Initially, acetyl transferases introduce an acetyl ester at C-7 or C-9 of sialic acid and under physiological conditions, the C-7 acetyl ester can migrate to C-8 or C-9 making C-9 acetylation (Neu5,9Ac_2) the most prevalent sialic acid modification of cell surface glycoconjugates.2,7 Acetylation of the C-4 hydroxyl of sialosides has also been observed.9

It has been shown that 9-O-acetylation of sialic acids can dramatically influence biological properties of glycoconjugates.2,7,9 For example, \(O\text{-}acetylation of sialosides on the surface of thymocytes results in loss of binding to Siglec-2 (CD22β) on B-cells.11 Abrogation of 9-O-acetylated deleteriously affects development of transgenic mice. This modification is also involved in cell specific recognition by influenza C and corona viruses.12,13 It has also been demonstrated that sialoglycoproteins having 9-O-acetylation are expressed on lymphoblasts of children with acute lymphoblastic leukemia.14

Glycoproteins and gangliosides from rat, mouse and chicken erythrocytes express Neu5,9Ac_2-\(\alpha\text{-}(2\rightarrow3)-Gal\beta-(1\rightarrow3)-GalNAc, which serves as targets for the binding of naturally occurring antibodies.12,15,16 In microorganisms, such as the trypanosoma parasite Crithidia fasciculata and the pathogenic fungus Cryptococcus...
**neoformans**, Neu5,9Ac₂ can be glycosidically linked to Gal-β-(1→3)-GalNAc. The potential impact of 9-O-acetylation of the GD₁₄ ganglioside on the overall conformation and recognition by a natural human antibody has been investigated by molecular dynamics simulations and NMR. It was found that acetylation did not affect the conformational properties of the oligosaccharide. However, it was shown that an antibody specific for a 9-O-acetylated ganglioside can make direct interactions with the acetyl group rationalizing the selective recognition of acetylated derivatives.

As part of a program to develop monoclonal antibodies against sialo-oligosaccharides bearing 9-O-acetyl esters, we report here an efficient chemo-enzymatic synthesis of Neu5,9Ac₂. The resulting compound can then be employed for the preparation of fully synthetic immunogens for the development of monoclonal antibodies.

### 2. Results and discussion

While relatively efficient methods have been developed for the introduction of sialosides, the preparation of acetylated analogues is less well developed. It was anticipated that compound 1 could be prepared by a regioselective chemical acetylation of Neu5Ac (2) to give 9-O-acetylated sialic acid 3, which can then be enzymatically converted into CMP-Neu5,9Ac₂ (4) employing the recombinant CMP-sialic acid synthetase from *Neisseria meningitidis*. This enzyme possesses a flexible substrate specificity and has been employed for the synthesis of CMP-sialic acid analogues such as CMP-Neu5,9Ac₂, Neu5,9Ac₂-O-Ser (1). It is to be expected that this compound can be employed for the preparation of fully synthetic immunogens for the development of monoclonal antibodies.

Sialyltransferases exhibit some flexibility with regard to the structure of their acceptors and are able to transfer modified sialic acids from corresponding CMP-derivatives. For example, a rat liver α(2→3)-sialyltransferase has been used to transfer Neu5,9Ac₂ from the corresponding CMP-donor to various glycoproteins, and a porcine liver α(2→6)-sialyltransferase has been employed for the chemo-enzymatic synthesis of Neu5,9Ac₂-α(2→6)-Gal-β-(1→4)-GlcNAC-α-OCH₃. Recently, a library of (2→6)-linked modified sialosides of Gal-β(1→4)-GlcNAC-α-O-(CH₂)₃N₃, which includes four 9-O-acetylated sialoside derivatives, has been prepared using the flexible recombinant *Photobacterium damsela* [EC 2.4.99.1] α(2→6)-sialyltransferase by a one-pot three-enzyme system. The enzymatic synthesis of the Neu5,9Ac₂-α(2→3)-Gal-O-p-nitrophenyl glycoside has also been reported.

It was anticipated that C-9 derivatives of sialic acid (Neu5Ac) would be readily available from Neu5Ac by a chemical regioselective acetylation. Thus, treatment of Neu5Ac (2) with trimethylorthoacetate in DMSO in the presence of a catalytic amount of p-TsOH•H₂O gave, after purification by an ion exchange column chromatography (Dowex 50W-X2, HCO₃⁻ form, eluent: a mixture of H₂O and formic acid) followed by a size exclusion chromatography (Biogel P-2; eluent: H₂O) Neu5,9Ac₂ (3) in an excellent yield of 92% (Scheme 1). Condensation of Neu5,9Ac₂ (3) with CTP in the presence of the commercial recombinant CMP-sialic acid synthetase from *N. meningitidis* [EC 2.7.7.43] and the inorganic pyrophosphatase from *Thermus thermophilus* [EC 3.1.3.1] afforded CMP-Neu5,9Ac₂ (4). The reported purification strategy gave a compound 4 contaminated with phosphorylated nucleotides (CTP, CDP and CMP) and a small amount of CMP-Neu5Ac and Neu5Ac. However, it was found that highly pure 4 could be obtained by removal of inorganic salts by selective precipitation in an ethanol–H₂O mixture (9:1, v:v, twice) followed by size exclusion chromatography over extra fine Biogel P-2 using ammonium bicarbonate buffer as eluent at 4 °C.

Glycosylation of thioglycoside 5 with properly protected serine derivative 6 in the presence of Ph₂SO-Tf₂O and DTBMP provided the α-linked glycopeptide 7 in 83% yield with excellent α-anomeric selectivity.

![Scheme 1](image-url)

Scheme 1. Reagents and conditions: (i) CH₃(OCH₃)₃, DMSO, p-TsOH-H₂O, 92%; (ii) CTP, 3, Tris buffer (0.1 M, pH 7.5), CMP-sialic acid synthetase, inorganic pyrophosphatase.
Scheme 2. Reagents and conditions: (i) Ph_2SO, DTBMP, CH_2Cl_2, -70 °C, Tf_2O then 6, 83%; (ii) (a) CH_3CO_2H–H_2O, 80 °C, 1 h; (b) Ac_2O, Py, DMAP, 92%; (iii) CH_3COSH, Py, 16 h, 67%; (iv) (a) TFA, H_2O, 1 h; (b) CH_3ONa, CH_3OH, pH < 10, 86%.

Scheme 3. Reagents and condition: (i): α-(2→3)-sialyltransferase, cacodylate buffer (50 mM, pH 6.2), alkaline phosphatase; Pd–C, CH_3OH–H_2O–H_2O–AcOH.

(Scheme 2). Treatment of 7 with aqueous acetic acid removed the benzylidene acetal and acetylation of the resulting free hydroxyls gave compound 8 in excellent overall yield. Next, the azido moiety of 8 was converted into an acetamido derivative by reaction with thioacetic acid in pyridine and the resulting compound 9 was treated with a mixture of TFA and water to remove the t-butyl ester, and then with NaOMe in methanol to cleave the acetyl esters to give glycopeptide 10.

At this stage of the synthesis, the Cbz group was kept intact because protection of the amino group of serine is required for glycopeptide synthesis.

Next, attention was focused on the enzymatic sialylation of 10 using a CMP-Neu5,9Ac_2 donor (Scheme 3). Thus, the recombinant rat α-(2→3)-sialyltransferase [EC 2.4.99.4] expressed in S. frugiperda and a calf intestine alkaline phosphatase [EC 3.6.1.1] were added to a mixture of 4 and 10 dissolved in cacodylate buffer (50 mM; pH 6.2) containing Triton X-100 and BSA. After incubation at 37 °C for 2 h, another portion of alkaline phosphatase and CMP-Neu5,9Ac_2 (4) was added and after occasional stirring for an additional 3.5 h, TLC analysis showed complete consumption of the starting material 4 and the formation of a new product. Purification of the crude reaction mixture by a reverse-phase C18 column chromatography followed by an ion exchange chromatography using Biorad AG 50W-X8 (100–200 mesh, Na⁺ form) at 4 °C, gave a pure trisaccharide 11 in a yield of 69%. In addition, a small amount (<5%) of 9-O-deacetylated product was also isolated.

Compound 11 is appropriately protected for glycopeptide synthesis. However, fully unprotected 1 could be obtained by catalytic hydrogenation over Pd–C to remove the N°-Cbz group followed by purification by a Biogel P-2 size exclusion column chromatography. The chemical shift of the C-9 protons clearly demonstrated the presence of the C-9 acetyl ester: 4.37 (dd, 1H, J = 2 Hz, H-9a) and 4.19 (dd, 1H, J = 2 Hz, H-9b).

In conclusion, we have developed an efficient chemoenzymatic synthesis of the trisaccharide 11, which is appropriately protected for glycopeptide synthesis. It has been shown that the rat recombinant α-(2→3)-sialyltransferase expressed in S. frugiperda can accept CMP-Neu5,9Ac_2 as a donor. The improved purification protocol for CMP-Neu5,9Ac_2 was essential for the successful transfer of CMP-Neu5,9Ac_2 to glycosyl acceptor Gal-β-(1→3)-GalNAc-O-Ser.

3. Experimental

3.1. General methods

The recombinant N. meningitidis CMP-sialic acid synthetase expressed in Escherichia coli [EC 2.7.7.43], the recombinant rat α-(2→3)-sialyltransferase [EC 2.4.99.4]
expressed in *S. frugiperda* and calf intestine alkaline phosphatase [EC 3.6.1.1] were purchased from Calbiochem. The inorganic pyrophosphatase from *T. thermophilus* [EC 3.1.3.1], bovine serum albumin (BSA), cytidine 5'-monophosphate (CMP), cytidine 5'-triphosphate (CTP), 1,4-dithioerythritol (DET), manganese(II) chloride (MnCl₂) and Triton X-100 were purchased from Sigma. All other chemicals were purchased from Aldrich. Solvents were dried using standard procedures, and all chemical reactions were performed under an atmosphere of Argon. Column chromatography was performed on F60 Silica Gel (60–200 μm) from Silicycle. Bio-Gel P-2 Gel fine (200–300 Da; 45–90 μm), Bio-Gel P-2 extra fine (200–300 Da, <45 μm) and AG 50W-X8 (100–200 mesh) ion exchange resin were obtained from Bio-Rad; preparative C₁₈ silica gel (125 Å, 55–105 μm) was obtained from Waters and Iatrobeads 6RS-8060 (60 μm) were purchased from Bioscan. Thin layer chromatography (TLC) was performed using Kieselgel 60 F₂₅₄ (Merck) plates with detection by UV and/or by charring with 5% sulfuric acid in ethanol, cerium ammonium nitrate or p-anisaldehyde reagents.

Solvent evaporations were done in vacuo with a bath temperature <25 °C. Optical rotations were measured with a Jasco P-1020 polarimeter. Both positive and negative ion matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectra were recorded using an Applied Biosystems 4700 instrument with gentisic acid as matrix. 1D and 2D1H NMR and 13C NMR spectra were recorded at 25 °C on Varian Inova300, Varian Inova600 or Varian Inova900 spectrometers. Assignments were obtained from COSY and HSQC spectra. For 1H spectra recorded in CDCl₃, D₂O and CH₃OD and 13C spectra recorded in CDCl₃, chemical shifts are given in ppm relative to solvents peaks (CDCl₃, 1H, 7.24; 13C, 77.00; D₂O, 1H, 4.76; CH₃OD, 1H, 3.31, 4.78). 13C Spectra recorded in D₂O were indirectly referenced.

### 3.2. N-(Benzyloxyacarbonyl) [4,6-di-O-acetyl-2-azido-2-deoxy-3-O-[3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)-β-D-galactopyranosyl]-1→3]-β-D-galactopyranosyl-L-serine t-butyl ester (8)

Ph₃PO (83 mg, 0.411 mmol), di-t-butyl-3-methyl pyridine (90.4 mg, 0.441 mmol) and activated molecular sieves 4 Å (500 mg) were added to a cooled solution (−70 °C) of disaccharide 5, (120 mg, 0.147 mmol) in CH₂Cl₂ (6 mL) prior to the addition of trifluoromethanesulfonic anhydride (58 mg, 0.36 μL, 0.205 mmol). After stirring the mixture at −70 °C for 5 min, a solution of 6 (85.5 mg, 0.29 mmol) in CH₂Cl₂ (0.5 mL) was added dropwise by syringe. The resulting reaction mixture was stirred at −60 °C for 1 h and then allowed to warm to room temperature over a period of 3 h. TLC analysis (hexanes-acetone 70:30, v:v) indicated completion of the reaction, which was quenched by the addition of solid NaHCO₃. After addition of CH₂Cl₂, the mixture was filtered, washed with H₂O, aqueous NaHCO₃ and brine, dried (MgSO₄), filtered and concentration in vacuo. The residue was purified by silica gel column chromatography (hexanes–EtOAc 65:35, v:v) to afford 7 (122 mg, 83%); [α]D +22 (c 0.2; CHCl₃); 1H NMR (CDCl₃): δ 7.30–7.00 (m, 13H, aromatics), 5.66 (d, 1H, J₈,₉ = 0.0 Hz, NH), 5.51 (m, 2H, H-2, CH₃ benzylidine), 5.43 (d, 1H, J₈ = 3.0 Hz, H-4'), 5.16 (dd, J₆,₇ = 3.0 Hz, J₇,₈ = 10.3 Hz, H-3'), 5.10 (s, 2H, PhCH₂), 4.91 (d, 1H, J₁₂ = 3.0 Hz, H-1), 4.86 (d, 1H, J₁₇ = 7.9 Hz, H-1'), 4.40–3.66 (m, 12H), 2.16, 2.03, 1.93 (3s, 3H each, 3 × CH₃, OAc), 1.44 (s, 9H, CH₃ t-Bu); 13C NMR: δ 170.5, 170.3, 137.7, 129.1 128.8, 128.6, 128.3, 126.3, 118.4, 118.1, 102.4 (C-1), 100.8 (PhCh), 99.9 (C-1), 83.1, 75.8, 75.7, 71.3, 71.1, 70.0, 69.9, 69.2, 67.3, 63.7, 61.6, 58.9, 55.1, 28.1, 20.9, 20.7; HRMALDI-ToF-MS: calcd for C₄₄H₅₂F₂N₄O₂₀ [M+Na]+: m/z: 1021.3231; found m/z: 1021.3224.

### 3.3. N-(Benzyloxyacarbonyl) [4,6-di-O-acetyl-2-azido-2-deoxy-3-O-[3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)-β-D-galactopyranosyl]-1→3]-β-D-galactopyranosyl-L-serine t-butyl ester (8)

A solution of disaccharide 7 (143 mg, 0.142 mmol) in a mixture of CH₃CO₂H (4 mL) and H₂O (1 mL) was kept at 80 °C for 1 h after which TLC analysis (hexanes–EtOAc 1:1, v:v) indicated completion of the reaction. The mixture was co-evaporated with tolune and the residue dried in vacuo. The recovered material was acetylated with pyridine (2 mL) and Ac₂O (0.2 mL) in the presence of a catalytic amount of dimethylaminopyridine (DMAP) for 12 h. After the addition of CH₃OH, the mixture was co-evaporated with toluene, the residue dissolved in CH₂Cl₂ and washed with aqueous NaHCO₃, H₂O and brine. The organic solvents were dried (MgSO₄), filtered and the filtrate concentrated in vacuo. The residue was purified by silica gel column chromatography (hexanes–acetone 70:30, v:v) to afford 8 (129 mg, 92%); [α]D +52.8 (c 0.2; CHCl₃); 1H NMR (CDCl₃): δ 7.3–7.0 (m, 8H, aromatics), 5.65 (d, 1H, J₈,₉ = 8.0 Hz, NH), 5.45–5.35 (m, 3H, H-4, H-2', H-4'), 5.16–5.08 (3H, H-3', PhCH₂), 4.85 (d, J₁₂ = 3.3 Hz, H-1), 4.77 (d, 1H, J₁₇ = 7.6 Hz, H-1'), 4.40 (m, 1H, H₂N Ser), 4.18–3.84 (m, 1H, 10H), 3.58 (dd, 1H, J₁₂ = 3.3 Hz, J₂,₃ = 0.7 Hz, H-2), 2.16, 2.10, 2.03, 2.02, 1.92 (5s, 15H, 5 × CH₃, OAc), 1.42 (s, 9H, CH₃, t-Bu); 13C NMR: δ 170.7, 170.6, 170.4, 170.2, 169.8 168.6, 136.3, 129.2, 128.8, 128.6, 128.5, 128.4, 101.5, 98.9, 83.1, 74.6, 71.2, 70.8, 70.1, 69.6, 69.4, 68.1, 67.3, 67.0, 62.8, 61.2, 59.6, 55.0, 28.0, 20.9, 20.8, 20.7; HRMALDI-ToF-MS: calcd for C₄₉H₅₂F₂N₄O₁₈ [M+Na]+: m/z: 1017.3124; found m/z: 1017.3141.
3.4. N-(Benzylxycarbonyl)-[2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-di-fluorobenzoyl)-β-d-galactopyranosyl)-1→3]-α-N-galacto-pyranosyl]-l-serine t-butyl ester (9)

Freshly distilled thiaoacetic acid (0.6 mL) was added by syringe to a solution of disaccharide 8 (128 mg, 0.128 mmol) in pyridine. The resulting reaction mixture was stirred under an atmosphere of argon for 18 h after which TLC (hexanes–EtOAc 1:1, v:v) indicated completion of the reaction. The mixture was diluted with CH2Cl2, successively washed with H2O, aqueous NaHCO3 and brine, dried (MgSO4), filtered and the filtrate concentrated in vacuo. The residue was purified by silica gel column chromatography (hexanes–EtOAc 55:45, v:v) to give 9 (86 mg, 67%); [α]D25 +66 (c 0.1; CHCl3); 1H NMR (CDCl3): δ 7.3–7.0 (m, 8H, aromatics), 5.55 (d, 1H, JH-1,Ha = 8.0 Hz, NH); 5.45–5.35 (m, 3H, H-4, H-2', H-4'); 5.16–5.30 (m, 3H, H-3', PhCH2); 4.78 (d, JH-1,b = 3.3 Hz, H-1), 4.68 (d, 1H, JH-1,b = 7.7 Hz, H-1'), 4.50 (m, 1H, H-2), 3.38 (m, 1H, H3Ser), 4.20–3.80 (m, 8H), 3.70 (dd, 1H, JH1,Ha = 3.0 Hz, JH1,Hb = 10.4 Hz, H3Ser), 2.14, 2.10, 2.03, 2.02, 1.92 (6s, 18H, 5 × CH3, OAc and NHAc), 1.39 (s, 9H, CH3-t-Bu); 13C NMR: δ 170.5, 170.4, 170.3, 170.1, 170.0, 169.5, 168.9, 135.9, 128.6, 128.5, 128.3, 118.4, 118.0, 100.5 (C-1'), 98.2 (C-1), 82.8, 74.8, 70.9, 70.7, 70.2, 68.6, 68.2, 67.8, 67.2, 66.7, 62.8, 60.8, 54.5, 48.2, 22.6, 20.7, 20.6, 20.5; HRM ALDI-ToF-MS: calcd for C36H42N2O12 [M+Na]+; m/z: 1033.3362; found m/z: 1033.3341.

3.5. N-(Benzylxycarbonyl)-[2-acetamido-2-deoxy-3-O-β-d-galactopyranosyl]-α-N-galactopyranosyl]-l-serine (10)

H2O (50 μL) was added to a solution of the disaccharide 9 (83 mg, 0.082 mmol) in trifluoroacetic acid (0.95 mL). The mixture was stirred at 22 ºC for 1 h until TLC (hexanes–acetonitrile 1:1, v:v) indicated completion of the reaction. The mixture was co-evaporated with toluene and the residue dried in vacuo. The crude material was dissolved in dry CH3OH (3 mL), and a solution of Na/Ba(OAc)2 in CH3OH (0.5 M) was carefully added while keeping the pH < 10 and the reaction monitored by TLC (CHCl3–CH3OH–H2O 65:35:5, v:v:v). The reaction was neutralized by the addition of Dowex 50W-X2 (H+ form). After filtration, the product was precipitated (presumably manganese–ammonium phosphosulfate) ammonium salt (4)

CTP (126 mg, 0.239 mmol) was added to a solution of Neu5,9Ac2 (50 mg, 0.144 mmol) in a Tris–HCl buffer (0.1 M, 9 mL, pH 7.5) containing DET (4.75 mM) and MnCl2 (13.80 mM). Addition of CTP resulted in a change of pH from 7.5 to 6.5, which was re-adjusted to pH 7.5 using aqueous NaOH (0.3 M). The recombinant CMP-sialic acid synthetase from N. meningitis (9.2 U, 27.0 μL) and the inorganic pyrophosphatase from T. thermophiles (4.6 U, 60.0 μL) were added, and the reaction mixture was incubated at 37 ºC for 1 h with occasional shaking. Another portion of CMP-sialic acid synthetase and inorganic pyrophosphatase (1.5 U, 19.5 μL) was added after 2.5 h. The formation of a white precipitate (presumably manganese–ammonium phosphos-
phate) was observed after 1.5 h. The progress of the reaction was monitored by TLC (EtOH:1 M NH4HCO3, 4:1, v:v), which after 5 h indicated completion of the reaction. Ethanol (80 mL) was added and the mixture was kept on ice for 2 h prior to centrifugation. The supernatant was decanted and the pellet (mostly inorganic salts) was re-suspended in EtOH (30 mL), cooled on ice for 1 h and centrifuged. The combined ethanol extracts were concentrated in vacuo providing crude material (230 mg). Ethanol (1.8 mL) was slowly added to the material dissolved in H2O (0.2 mL) and precipitation occurred immediately. The mixture was kept on ice for 2 h, and the supernatant was removed after centrifugation. After drying, NMR (D2O) of the first pellet (114 mg) indicated the presence of the expected product, some Tris, ethanol and a small amount of Neu5,9Ac2. The recovered material was again dissolved in H2O (0.2 mL) and re-precipitated by the addition of ethanol (1.80 mL) as described above providing 75 mg of material, which was loaded on a column of extra-fine Biogel P-2 (75 × 1.5 cm) and eluted with 0.1 M NH4HCO3 at 4°C. The supernatant was decanted and the pellet (4:1, v:v), which after 5 h indicated completion of the reaction was monitored by TLC (EtOH–1 M NH4CH3CO2 8:2, v:v) indicating completion. The recovered material was purified by C-18 silica gel (5 g) column chromatography using a gradient of CH3CN in H2O (95:5→90:10, v:v, at 4°C), which removed the 9-O-deacetylated trisaccharide (1.0 mg) from the product (22.5 mg, 69%); 1H NMR (600 MHz): δ 7.40 (m, 5H, aromatics), 5.18–5.08 (m, 2H, PhCH2), 4.85 (d, 1H, J1,2 = 3.3 Hz, H-1), 4.50 (d, 1H, J1,2 = 7.6 Hz, H-1′), 4.35 (br d, 1H, Jα,β = 10.7 Hz, H-9′a), 4.28 (dd, 1H, J1,2 = 3.3 Hz, J2,3 = 11.0 Hz, H-2), 4.20–4.15 (m, 3H, H-4, H-9′b, HxSer), 4.08–4.00 (m, 3H, H-3, H-3′, H-′3′), 3.95–3.90 (m, 3H), 3.83 (t, 1H, J4,4′′ = J4,4′′ = 10.1 Hz, H-5′), 3.78 (m, 1H, HβSer), 3.73–3.55 (m, 8H), 3.50 (dd, 1H, J1,2 = 7.6 Hz, J1,2 = 9.4 Hz, H-2′), 2.74 (dd, 1H, Jeq,3eq = 4.6 Hz, Jeq,3eq = 12.5 Hz, H-3′eq), 2.10 (s, 3H, OAc), 2.01, 1.95 (2s, 6H, NH2Ac), 1.77 (t, 1H, Jα,β = 12.5 Hz, H-3′ax) HRMALDI-ToF-MS: cale for C38H52N6O24 [M+Na]+: mz: 960.3342; found 960.3351.

3.9. (5-Acetamido-9-O-acetyl-3,5-dideoxy-d-glycero-α-D-galacto-2-nonulopyranosyl acid)-(2→3)-O-(β-D-galactopyranosyl)-(1→3)-O-(2-acetamido-2-deoxy-α-D-galactopyranosyl)-l-serine acetate (1) 

Recombinant rat α-(2→3)-sialyltransferase from S. frugiperda [EC 2.4.99.4] (10 μU, 7 μL) and calf intestine alkaline phosphatase (15 U, 15 μL) were added to a mixture of disaccharide 11 (20.0 mg, 0.021 mmol) in a mixture of H2O and CH3OH (1:1, 3.5 mL) containing CH3CO2H (0.14 mL). The mixture was hydrogenated at 1 atm for 30 min after which TLC (CH32OH–1 M NH42CO2 8:2, v:v) indicated completion of the reaction. The mixture was filtered through a 0.2 μm PTFE syringe filter, the solvents were evaporated and the residue was freeze dried from H2O to provide trisaccharide 11 (18.1 mg, 100%). 1H NMR (900 MHz): δ 4.91 (d, 1H, J1,2 = 3.0 Hz, H-1), 4.52 (d, 1H, J1,2 = 7.7 Hz, H-1′), 4.37 (dd, 1H, Jγ,γ′ = 2.2 Hz, Jγ,γ′ = 12.0 Hz, H-9′a), 4.35 (dd, 1H, J1,2 = 3.2 Hz, J2,3 = 11.0 Hz, H-2), 4.23 (d, 1H, J3,4 = 2.5 Hz, H-4), 4.19 (dd, 1H, Jγ,γ′ = 5.8 Hz, Jγ,γ′ = 12.0 Hz, H-9′b), 4.11 (dd, 1H, J3,4 = 2.8 Hz, J3,4 = 11.2 Hz, HxSer), 4.09–4.03 (m, 3H, H-3, H-3′, H-′3′), 3.97 (m, 2H, HβSer, H-5), 3.92 (d, 1H, J5,6 = 3.0 Hz H-4′), 3.88 (dd, 1H, H-3′ax).
Acknowledgement

This research was supported by the National Cancer Institute of the National Institute of Health (Grant No. RO1 CA88986).

Supplementary data

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.carres.2008.05.002.

References

1. Schauer, R. Zoology (Jena) 2004, 107, 49–64.
2. Traving, C.; Schauer, R. Cell. Mol. Life Sci. 1998, 54, 1330–1349.
3. Angata, T.; Varki, A. Chem. Rev. 2002, 102, 439–469.
4. Nakamura, K.; Kojima, H.; Suzuki, M.; Suzuki, A.; Tamai, Y. Eur. J. Biochem. 2000, 267, 5198–5208.
5. Vankar, Y. D.; Schmidt, R. R. Chem. Soc. Rev. 2000, 29, 201–216.
6. Brocke, C.; Kunz, H. Bioorg. Med. Chem. 2002, 10, 3085–3112.
7. Schauer, R. Glycoconjugate J. 2000, 17, 485–499.
8. Butor, C.; Diaz, S.; Varki, A. J. Biol. Chem. 1993, 268, 10197–10206.
9. Tiralongo, J.; Schmid, H.; Thun, R.; Iversen, M.; Schauer, R. Glycoconjugate J. 2000, 17, 849–858.
10. Lewis, A. L.; Cao, H.; Patel, S. K.; Diaz, S.; Ryan, W.; Carlin, A. F.; Thun, V.; Lewis, W. G.; Varki, A.; Chen, X.; Nizet, V. J. Biol. Chem. 2007, 282, 27562–27571.
11. Sjoberg, E. R.; Powell, L. D.; Klein, A.; Varki, A. J. Cell Biol. 1994, 126, 549–562.
12. Rogers, G. N.; Herrler, G.; Paulson, J. C.; Klenk, H. D. J. Biol. Chem. 1986, 261, 5947–5951.
13. Kunkel, F.; Herrler, G. Virology 1993, 195, 195–202.
14. Mandal, C.; Chatterjee, M.; Sinha, D. Br. J. Haematol. 2000, 110, 801–812.
15. Gowda, D. C.; Reuter, G.; Shukla, A. K.; Schauer, R. Hoppe-Seylers Z. Physiol. Chem. 1984, 365, 1247–1253.
16. Siebert, H. C.; von der Lieth, C. W.; Dong, X.; Reuter, G.; Schauer, R.; Gabius, H. J.; Vliegenthart, J. F. Glycobiochemistry 1996, 6, 561–572.
17. Matta, M. A. D.; Alviano, D. S.; Couceiro, J. N. D. S.; Nazareth, M.; Meirelles, L.; Alviano, C. S.; Angluster, J. Parasitol. Res. 1999, 85, 293–299.
18. Rodrigues, M. L.; Rozental, S.; Couceiro, J. N. S.; Angluster, J.; Alviano, C. S.; Travassos, L. R. Infect. Immun. 1997, 65, 4937–4942.
19. Pal, S.; Chatterjee, M.; Bhattacharya, D. K.; Bandhyopadhyay, S.; Mandel, C. Glyobiology 2000, 10, 539–549.
20. Buskas, T.; Ingle, S.; Boons, G. J. Angew. Chem., Int. Ed. 2005, 44, 5985–5988.
21. Ingle, S.; Woffert, M. A.; Gaekwad, J.; Buskas, T.; Boons, G. J. Nat. Chem. Biol. 2007, 3, 663–667.
22. Bundle, D. R. Nat. Chem. Biol. 2007, 3, 604–606.
23. Ogura, H.; Furuhatata, K.; Sato, S.; Anazawa, K.; Itoh, M.; Shitori, Y. Carbohydr. Res. 1987, 167, 77–86.
24. Auge, C.; Fernandez-Fernandez, R.; Gautheron, C. Carbohydr. Res. 1990, 200, 257–268.
25. Higa, H. H.; Paulson, J. C. J. Biol. Chem. 1985, 260, 8838–8849.
26. Schultz, M.; Kunz, H. Tetrabedron: Asymmetry 1993, 4, 1205–1220.
27. Blixt, O.; Paulson, J. C. Adv. Synth. Catal. 2003, 345, 687–690.
28. Gross, H. J.; Rose, U.; Krause, J. M.; Paulson, J. C.; Schmid, K.; Feeney, R. E.; Brossmer, R. Biochemistry 1989, 28, 7386–7392.
29. Yu, H.; Huang, S. S.; Chokhawala, H.; Sun, M. C.; Zheng, H. J.; Chen, X. Angew. Chem., Int. Ed. 2006, 45, 3938–3944.
30. Chokhawala, H. A.; Yu, H.; Chen, X. Chembiochem 2007, 8, 194–201.
31. Simon, E. S.; Bednarski, M. D.; Whitesides, G. M. J. Am. Chem. Soc. 1988, 110, 7159–7163.
32. Cato, D.; Buskas, T.; Boons, G. J. J. Carbohydr. Chem. 2005, 24, 503–516.
33. Rosen, T.; Lico, I. M.; Chu, D. T. W. J. Org. Chem. 1988, 53, 1580–1582.
34. Klich, G.; Paulsen, H.; Meyer, B.; Meldal, M.; Bock, K. Carbohydr. Res. 1997, 299, 33–48.
35. Shangguan, N.; Katukojvala, S.; Greenberg, R.; Williams, L. J. J. Am. Chem. Soc. 2003, 125, 7754–7755.
36. Bezay, N.; Dudziak, G.; Liese, A.; Kunz, H. Angew. Chem., Int. Ed. 2004, 43, 2292–2295.
37. Ajsaka, K.; Miyasato, M. Biosci. Biotech. Biochem. 2000, 64, 1743–1746.